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ABSTRACT 33 
Existing therapies for leishmaniases present significant limitations, such as toxic side 34 
effects, and are rendered inefficient by parasite resistance. It is of utmost importance to 35 
develop novel drugs targeting Leishmania that take these two limitations into 36 
consideration. We thus chose a target-based approach using an exo-protein kinase, 37 
Leishmania casein kinase 1.2 (LmCK1.2) that was recently shown to be essential for 38 
intracellular parasite survival and infectivity. We developed a four-step pipeline to 39 
identify novel selective anti-leishmanial compounds. In step 1, we screened 5018 40 
compounds from kinase-biased libraries with Leishmania and mammalian casein kinase 1 41 
in order to identify hit compounds and assess their specificity. For step 2, we selected 88 42 
compounds among those with the lowest IC50 to test their biological activity on host-free 43 
parasites using a resazurin reduction assay and on intramacrophagic amastigotes using a 44 
high content phenotypic assay. Only seventy-five compounds showed anti-leishmanial 45 
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activity and were retained for step 3 to evaluate their toxicity against mouse macrophages 46 
and human cell lines. The four compounds that displayed a selectivity index above 10 47 
were then assessed for their affinity to LmCK1.2 using a target deconvolution strategy in 48 
step 4. Finally, we retained two compounds, PP2 and compound 42, for which LmCK1.2 49 
seems to be the primary target. Using this four-step pipeline, we identify from several 50 
thousand molecules, two lead compounds with a selective anti-leishmanial activity.   51 
 52 
INTRODUCTION 53 
The protozoan parasite Leishmania is the causative agent of leishmaniasis, a potentially 54 
fatal disease with worldwide distribution. Depending on the species, three clinical forms 55 
of the disease can be distinguished, cutaneous (CL, e.g. L. major), mucocutaneous (MCL, 56 
e.g. L. braziliensis) and fatal visceral leishmaniasis (VL, e.g. L. donovani) (1). Several 57 
treatment options are available, which either show important side effects or are 58 
unaffordable. In all endemic regions, the first line of treatment is pentavalent antimonials, 59 
despite their important side effects and the appearance of parasite resistance. Although 60 
their target has not been identified, one member, sodium stibogluconate was shown to 61 
inhibit the energy metabolism and macromolecule biosynthesis (2) (3). The second line of 62 
treatment is Amphotericin B, a very potent but highly toxic antifungal drug. This 63 
compound creates pores targeting ergosterol only present in the plasma membrane of 64 
parasites but not in that of mammalian cells. Its less toxic lipid formulation is extremely 65 
expensive and thus incompatible with treatment in developing countries (3, 4). Among 66 
the other drugs that have been recently developed, miltefosine was a major breakthrough 67 
in leishmaniasis therapy as this anticancer drug is the first oral treatment against VL. 68 
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Unfortunately, its teratogenicity excludes the treatment of pregnant women and its slow 69 
turnover could promote the emergence of clinical parasite resistance (4). Miltefosine 70 
plays a role in the perturbation of the lipid metabolism, the induction of apoptosis-like 71 
cell death and has immuno-stimulatory effects; however its mode of action has not been 72 
precisely identified (5). The activity of miltefosine is due to its accumulation inside the 73 
parasite (6), which is prevented in resistant lines generated in vitro by the overexpression 74 
of members of the ABC (ATP-binding cassette) transporter family and/or mutation of the 75 
flippase LdMT (6) (7). Three more drugs complete the list of available treatments for 76 
Leishmaniasis: (i) pentamidine, which has been used for VL, CL and MCL treatment, 77 
induces the inhibition of polyamine biosynthesis and a decrease of the mitochondrial 78 
inner membrane potential, (ii) the aminoglycosidic antibiotic paromomycin, which is 79 
restricted to endemic areas, cures both VL and CL efficiently by targeting mitochondria, 80 
and (iii) sitamaquine, an 8-aminoquinoline, which intercalates within biological 81 
membranes to accumulate in Leishmania cytosolic acidic compartments (4).  82 
Despite the various drugs available, none of these treatments are ideal because of two 83 
main aspects: (i) their side effects, due mainly to off-target effects that cannot be 84 
eliminated by drug optimization as the target responsible for the anti-leishmanial effect is 85 
unknown, and (ii) the emergence of parasite resistance, due to the plasticity of the 86 
parasite. Therefore there is an urgent need to discover new molecules and to develop new 87 
drug discovery pipelines that take these two aspects into consideration. First, the use of 88 
known validated targets for drug screening represents a major advantage as the 89 
compound could be optimized to fit exclusively the target, avoiding off-target effects 90 
mainly responsible for side effects. Protein kinases are among the best candidates as drug 91 
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targets for leishmaniasis because: (i) kinase inhibitors are one of the most important 92 
group of FDA-approved drugs for the treatment of diseases such as cancer or Alzheimer 93 
disease, (ii) they are considered as valid targets for diseases caused by unicellular 94 
parasites, such as malaria, and (iii) kinases regulate many key processes, such as cell 95 
cycle or signal transduction and thus the inhibition of their activity decreases cell viability 96 
(8) (9-14). Second, targeting proteins secreted by the parasite could delay the emergence 97 
of drug resistance. Indeed it has been recently shown that parasitic proteins could be 98 
exported, via exosomes, into the host cell to modify its biology or its innate immune 99 
response (15) (16). To perform their function in the host, these proteins need to interact 100 
with host proteins and thus any mutations could abrogate their functions in the host cell, 101 
which could be detrimental for the intracellular parasite survival.  102 
 103 
Among the proteins identified in the recent proteomic analysis of Leishmania exosomes, 104 
13 could qualify as good drug targets as defined above because they are excreted kinases. 105 
Most of these kinases are involved in purine or glucose metabolism, and only one is 106 
involved in signal transduction, casein kinase 1. Member of a highly conserved Ser/Thr 107 
protein kinase family (17), casein kinase I contains six isoforms in Leishmania (15, 18-108 
20). LmjF35.1010 (LmCK1.2), the major isoform, has been validated pharmacologically 109 
as a drug target based on the findings that the inhibition of CK1 activity by the specific 110 
inhibitor D4476 strongly compromises axenic amastigote viability and decreases the 111 
percentage of infected macrophages (21). We hypothesize that the capacity of LmCK1.2 112 
to recognize and phosphorylate host proteins could allow the parasite to regulate essential 113 
host cell processes (22) and therefore to survive. This hypothesis is based on our previous 114 
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findings showing that (i) the protein sequence of LmCK1.2 kinase domain is 100% 115 
identical in all sequenced Leishmania species (except the lizard-isolated L. tarentolae and 116 
unclassified L. sp. MAR LEM2494), suggesting that there is a selection pressure to 117 
maintain the integrity of the protein sequence, and (ii) LmCK1.2 is the most closely 118 
related kinase to its human orthologs in Leishmania. These two elements suggest that 119 
LmCK1.2 cannot be mutated without compromising the survival of the intracellular 120 
parasite, which would render the emergence of drug resistant parasites expressing 121 
mutated LmCK1.2 unlikely (21).  122 
Here we present a four-step pipeline that allows the discovery of novel lead compounds. 123 
First, we generated an active recombinant LmCK1.2 and purified mammalian CK1 from 124 
porcine brain (SsCK1, (23)). We developed an enzymatic assay to screen 4030 125 
compounds from kinase-biased and focused libraries as well as 988 analogs with both 126 
Leishmania and mammalian kinases in order to identify hit compounds and assess their 127 
specificity. We selected 88 compounds with an IC50 below 10 μM. Second, we tested the 128 
anti-leishmanial effect of these compounds on cultured parasites using a rezasurin-based 129 
assay as well as on intracellular parasites using a high content phenotypic screen. We 130 
retained seventy-five compounds with an anti-leishmanial activity. Third, after evaluation 131 
of the toxicity of the selected anti-leishmanial compounds against mouse macrophages 132 
and human cell lines, only four compounds had a selectivity index (SI) above 10. Fourth, 133 
the affinity for LmCK1.2 for these compounds was tested using a target deconvolution 134 
approach. Two compounds for which LmCK1.2 seems to be the primary target were 135 
eventually selected. The identification of these two lead compounds validates our 136 
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pipeline, which will be used to screen diversified libraries to identify more lead 137 
compounds. 138 
 139 
MATERIAL AND METHODS 140 
L. donovani culture and axenic amastigote differentiation. 141 
L. donovani 1S2D (MHOM/SD/62/1S-CL2D), clone LdB, was obtained from Steve 142 
Beverley, Washington University School of Medicine, St. Louis, USA and cultured as 143 
described (24-26).  144 
 145 
Parasite growth inhibition assay.  146 
L. donovani promastigotes and axenic amastigotes (2x106 cells/ml) in their respective 147 
media were distributed in 96 well plates (125 µl/well). An equal volume of medium 148 
containing inhibitor at the indicated concentrations (in 1% of dimethyl sulfoxide final 149 
concentration, DMSO) was added. After 24h incubation in the dark at 26°C 150 
(promastigotes) or 37°C (amastigotes), 25 µl of resazurin solution at 0.001% was added 151 
and the plates were incubated for an additional 24h in the dark at appropriate 152 
temperatures. The plates were read (λex: 544 nm; λem: 590 nm) using a fluorescent 153 
microplate reader (Safas xenius XML) (27).  154 
 155 
Human cell lines MTT.  156 
HFF1, SH-SY5Y and U-2 OS cells were cultured in Dulbecco's modified Eagle's medium 157 
(DMEM), hTERT RPE-1 were cultured in DMEM:F12 medium. All media were 158 
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 IU penicillin and 159 
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streptomycin. Cell viability was assayed using the ‘CellTiter96 AQueous non-radioactive 160 
cell proliferation assay’ test (MTS) from PROMEGA according to manufacturer’s 161 
instructions. 162 
 163 
Macrophage infection and assessment of intracellular parasite survival. 164 
A high content, biologically relevant cell-based assay was used to determine the anti-165 
leishmanial activity of D4476 as previously described (21, 28). Briefly, the assay 166 
combines (1) the use of primary bone marrow-derived mouse macrophages as natural 167 
host cells and DsRed2-expressing amastigotes of L. amazonensis 168 
(MPRO/BR/1972/M1841), the clinically relevant parasite stage of Leishmania with (2) 169 
the detection of fluorescent markers as reporter molecules. 10,000 macrophages were 170 
counted per well depending on the number of replicates per tested compound.  171 
 172 
Ethics statement.  173 
All animals were housed in our A3 animal facilities in compliance with the guidelines of 174 
the A3 animal facilities at the Institut Pasteur, which is a member of Committee 1 of the 175 
“Comité d'Ethique pour l'Expérimentation Animale” (CEEA) - Ile de France - Animal 176 
housing conditions and the protocols used in the work described herein were approved by 177 
the “Direction des Transports et de la Protection du Public, Sous-Direction de la 178 
Protection Sanitaire et de l’Environnement, Police Sanitaire des Animaux under number 179 
B75-15-27 and B75-15-28 in accordance with the Ethics Charter of animal 180 
experimentation that includes appropriate procedures to minimize pain and animal 181 
suffering. GS and EP are authorized to perform experiment on vertebrate animals (licence 182 
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B75-1159 and 75-1265, respectively) issued by the “Direction Départementale de la 183 
Protection des Populations de Paris” and is responsible for all the experiments conducted 184 
personally or under his supervision as governed by the laws and regulations relating to 185 
the protection of animals. 186 
 187 
Automated microtiter plate CK-S kinase assay.  188 
A mixture of native CK1 isoforms (essentially CK1δ and CK1ε) was extracted from 189 
porcine brain (SsCK1) and purified by affinity chromatography on immobilised axin 190 
(23). LmCK1.2 was produced and purified as previously described (21). Both SsCK1 and 191 
recombinant LmCK1.2 were assayed, with 27 µM CK-specific peptide substrate CK-S 192 
(RRKHAAIGpSAYSITA) synthesized by Proteogenix (Oberhausbergen, France), in 193 
buffer C pH 7 (60 mM β-glycerophosphate, 30 mM p-nitrophenyl phosphate, 25 mM 194 
MOPS, 5 mM EGTA, 15 mM MgCl2, 1 mM dithiothreitol, 0.1 mM sodium vanadate), 195 
with 15 µM [γ-33P] ATP in a final volume of 30 µl. After 30 min incubation at 30°C, 30 196 
µL aliquots were filtered onto whatman P81 phosphocellulose paper. The filters were 197 
washed with a solution of 1% phosphoric acid then counted in the presence of 20 µl 198 
scintillation fluid per well. Blank values were subtracted and activities calculated as 199 
pmoles of phosphate incorporated during the 30 min incubation. The activities were 200 
expressed in percent of maximal activity, i.e. in the absence of inhibitors. Controls were 201 
performed with appropriate dilutions of DMSO.  202 
 203 
ATP depletion and competition  204 
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Seven mg of axenic amastigote total protein extract were dialyzed overnight at 4°C in 205 
dialysis solution (1X PBS, 1 mM EDTA, 1 mM DTT) using a Slide-A-Lyzer 10kD 206 
dialysis cassette (Pierce) to eliminate free ATP. One mg of dialyzed extract per condition 207 
was mixed with the binding solution (1X Binding solution, 1mM DTT, 1X Protease 208 
inhibitor) of the ATP affinity test kit (Jena Bioscience) and 500 µM of inhibitor. The 209 
samples were incubated 30 min at 4°C and added to a mixture of 12.5 µl of each ATP 210 
agarose (ATP affinity test kit from Jena Bioscience). ATP binding proteins from the 211 
assay and the competition samples were enriched according to the manufacturer’s 212 
instructions. Finally, eluted samples were concentrated using Amicon Ultra 10K 213 
centrifugal filters (Millipore) to a final volume of approximately 100 µl.  214 
12.5 µl of the flow through and 30 µl of the eluate were separated on Novex NuPAGE 4-215 
12% bis tris gel (Life technologies) from both the assay and the competition. The gel was 216 
stained with SYPRO Ruby (Life technologies) according to the manufacturer’s 217 
instructions and revealed using a Typhoon scanner. Alternatively, proteins separated by 218 
SDS-PAGE were transferred onto a PVDF membrane and probed with SY3535 antibody 219 
(21). Signals were revealed by Super Signal ECL (Pierce). 220 
 221 
Compound libraries 222 
We screened 5018 compounds from the Roscoff library including 588 purine derivatives 223 
(29) and  400 indirubin derivatives (30) (31) (32). 224 
  225 
Homology modeling and structural alignment 226 
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The amino acid sequence of L. major CK1.2 was retrieved from NCBI database 227 
(Accession number: XP_003722496) in FASTA format. The homology modeling of the 228 
sequence was performed by SWISS-MODEL program (33) and the protein with PDB 229 
code 3SV0 was selected as a template. PyMOL program (34) was used for the structural 230 
alignment of Schizosaccharomyces pombe casein kinase 1 in complex with the specific 231 
CK1 inhibitor, IC261 (PDB code: 1EH4) and Homo sapiens casein kinase 1δ (PDB code: 232 
4KB8) to the generated L. major CK1.2 homology model. The figures were also prepared 233 
using PyMOL (34). 234 
 235 
RESULTS 236 
We present below, a comprehensive drug discovery pipeline encompassing four steps. 237 
STEP 1: Identification of specific LmCK1.2 inhibitors. 238 
Primary screening comparing SsCK1 and LmCK1.2  239 
We purified recombinant LmCK1.2-V5-His6 from E. coli and a mixture of Sus scrofa 240 
CK1δ and CK1ε (SsCK1) from porcine brain (21) (23). The conditions used previously 241 
for the manual kinase assay were adapted to an automated 96-well plate format (23) (21). 242 
We used CK-S as substrate for both kinases, and 15 µM [γ-33P] ATP (23) (21). We 243 
screened 4030 compounds at 10 μM from a kinase-biased library that has been previously 244 
tested on mammalian kinases, such as Cyclin-Dependent Kinases (CDK) (29). For each 245 
compound, the percentage of inhibition of LmCK1.2 versus that of SsCK1 is presented in 246 
Figure 1A. We classified as hit compounds those that decreased the kinase activity by 247 
more than 40% (Figure 1A a and b). We obtained twice as much hit compounds for the 248 
mammalian CK1 than for LmCK1.2 (Figure 1B). Indeed, we identified 245 hit 249 
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compounds against SsCK1 (6.1% Hit rate) and 128 against LmCK1.2 (3.2% Hit rate) 250 
with only 37 compounds with a similar potency against both kinases. This finding, which 251 
is surprising considering the high similarity between the protein sequences of LmCK1.2 252 
and the mammalian CK1s (about 70% (21)), suggests that the ATP binding pocket of the 253 
two kinases is sufficiently divergent to accommodate different inhibitors. We next 254 
classified the compounds according to their potency and specificity (Class 1 corresponds 255 
to compounds that inhibit the kinase activity between 80-100%, Class 2 between 60-80%, 256 
and Class 3 between 40-60%, Figure 1C). We obtained a similar number and distribution 257 
of hit compounds active on SsCK1 (30 compounds) and on LmCK1.2 (31 compounds) in 258 
Class 1. In contrast, we observed an increased number of compounds inhibiting 259 
specifically SsCK1 in Class 2 and 3 (Figure 1C). This could suggest that the ATP binding 260 
pocket of SsCK1 could be more permissive than that of LmCK1.2. We selected 45 261 
compounds either belonging to Class 1 that inhibited LmCK1.2 activity by more than 262 
90% or that belong to Class 2 and were specific to LmCK1.2 to determine their IC50. As 263 
shown in Figure 2, all the compounds with an IC50 below 1.3 μM (most potent) were not 264 
specific, whereas all the specific compounds had an IC50 above 1.3 μM.  265 
Among the 45 compounds that were potent against LmCK1.2, we identified several 266 
inhibitors described to have anti-leishmanial activity, including known CK1 inhibitors, 267 
such as anthraquinone (35-37), or compounds for which we revealed CK1 as a new 268 
target, such as Gossypol, purpurogallin and some flavonoids (38-41) (42) (43). These 269 
compounds, identified from several libraries, were found at least twice with similar IC50, 270 
indicating that our assay is reproducible (data not shown). Altogether, these data 271 
demonstrate the efficiency of using CK1 as a target to identify compounds with anti-272 
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leishmanial activities and confirm LmCK1.2 as a valid drug target. However we did not 273 
retain these compounds for subsequent characterization as they have been already 274 
extensively studied. 275 
Secondary screening of purine and indirubin libraries  276 
Out of the 45 compounds for which we determined the IC50, we selected 2 compounds 277 
with low IC50 but only moderate specificity towards LmCK1.2, purvalanol B and 278 
indirubin-3’-monoxime, and tested analog libraries to perform SAR analysis in order to 279 
identify more specific compounds. We chose purvalanol B because we showed 280 
previously that Leishmania CK1.2 binds to purvalanol B better than its mammalian 281 
counterpart, suggesting that the sensitivity to purvalanol B could be higher for LmCK1.2 282 
than for SsCK1 (44). Confirming this finding, the IC50 of purvalanol B towards LmCK1.2 283 
(2 +/- 0.3 μM) is slightly lower than that towards SsCK1 (2.9 +/- 1.2 μM). We tested the 284 
potency of 588 purine analogs (Figure 3A) at 10 μM against LmCK1.2 and SsCK1 to 285 
identify compounds with better potency and/or specificity. As shown in Figure 3B and 286 
3C, most compounds were more potent against mammalian CK1 than against LmCK1.2 287 
(below the black line, Figure 3B and dark grey in Figure 3C). Next, we determined the 288 
IC50 of the 21 most potent purine derivatives against LmCK1.2 (Figure 3D). For all the 289 
compounds, except one, the IC50 was systematically higher against LmCK1.2 (0.44 to 2.4 290 
μM) than against mammalian CK1 (0.081 to 1.6 μM). Only compound 26 had a lower 291 
IC50 against LmCK1.2 (1 +/- 0.4 μM) than against SsCK1 (3.7 +/- 1.2 μM), which could 292 
be due to the presence of a long carbon chain, a unique feature compared to the other 293 
derivatives. Thus although the purines were very potent towards LmCK1.2, they present a 294 
higher affinity for SsCK1.  295 
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The second family of compounds we screened are the indirubins (Figure 4A). We showed 296 
that the IC50 of indirubin-3’-monoxime is lower against LmCK1.2 (0.13 +/- 0.03; Table 297 
S1) than against mammalian CK1 (0.39 +/- 0.08 μM; Table S1). To identify better 298 
compounds with higher selectivity, we tested 400 indirubin derivatives (Figure 4B). 299 
Contrary to the purine analogs, the indirubins were globally more potent against 300 
LmCK1.2 than SsCK1 (Figure 4B). For instance, in Class 1, forty-six compounds were 301 
more specific toward LmCK1.2 than SsCK1 versus only 9 were more specific towards 302 
SsCK1 than LmCK1.2 (Figure 4C). Indeed, the most active compounds were the most 303 
selective toward LmCK1.2, whereas compounds with lower potency (Class 3) were more 304 
specific toward SsCK1 (Figure 4C). We selected the 55 most potent compounds to 305 
measure their IC50. They were comprised between 0.08 and 10 μM, and for almost all the 306 
compounds, the IC50 against LmCK1.2 was systematically lower than that against 307 
mammalian CK1 (Figure 4D), suggesting that the indirubin compounds have more 308 
affinity towards LmCK1.2 than SsCK1.  309 
The differences in specificity observed with the purine and indirubin compound families 310 
confirm that important differences exist between the ATP binding pocket of both kinases 311 
(21). It also suggests that due to the strong affinity of the purine for the mammalian CK1, 312 
it is likely that these compounds will be toxic for the host cell.  313 
Among all the compounds identified in the primary and secondary screenings, we 314 
eliminated all the compounds for which the chemical optimization was unfeasible and 315 
selected 12 compounds from the main library, 21 compounds from the purine library and 316 
55 compounds from the indirubin library to assess their anti-leishmanial activity. 317 
 318 
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STEP 2: Evaluation of the anti-leishmanial activity of selected compounds. 319 
We evaluated the anti-leishmanial activity of the 88 compounds selected in STEP 1 on 320 
cultured L. donovani promastigotes and axenic amastigotes by measuring the percentage 321 
of metabolically active parasites in liquid culture using the rezasurin-based assay (27) 322 
(Table S1). As a positive control, we treated the parasites with 1 µM of the anti-323 
leishmanial reference drug, AMB and obtained a growth inhibition of 90.4 ± 1.5 % and 324 
79.9 ± 1.3 % for promastigotes and amastigotes, respectively, with excellent 325 
reproducibility as reported by the small standard deviation values.  326 
We then tested the compounds against intracellular L. amazonensis using a visual high 327 
content phenotypic assay (21, 28). We measured three parameters: (i) the percentage of 328 
cells remaining after treatment compared to the vehicle control (DMSO) to evaluate cell 329 
detachment (Total Macrophages, TM), (ii) the percentage of healthy cells compared to 330 
the total number of cells remaining after treatment to evaluate cell mortality (Viability 331 
Index, VI), and (iii) the percentage of parasitophorous vacuoles per healthy cell to 332 
evaluate the parasite burden (PB). We used AMB at 0.5 μM and cycloheximide (CHX) at 333 
150 μM as anti-leishmanial and cytotoxic control compounds, respectively. Figure S1 334 
presents the data of all the controls performed during the screening campaign. As 335 
expected, AMB is reducing parasite burden without affecting the number of macrophages 336 
or their viability, whereas CHX does not affect significantly the number of macrophages 337 
but decreases dramatically the viability, as it is extremely toxic to macrophages. The data 338 
were reproducible as judged by the small standard deviation values, (Figure S1).  339 
For each of the 88 compounds, we plotted the percentage of metabolically active 340 
promastigotes or amastigotes at 10 μM versus the percentage of parasite burden at 10 μM 341 
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(Figure 5). We considered as efficient, those compounds that decreased the percentage of 342 
metabolically active parasites or the percentage of parasite burden by 40%. We 343 
eliminated compounds that had no effect on the percentage of intracellular parasites; 344 
remarkably those compounds were also mainly inefficient on cultured parasites (Figure 5, 345 
b and d). Among the 65 compounds that were potent towards the intracellular parasites, 346 
we identified two categories: compounds equally efficient on cultured and intracellular 347 
parasites (Figure 5, c) and compounds that were only efficient on intracellular parasites, 348 
which represent the majority of the compounds (43 out of 65 for promastigotes and 57 349 
out of 65 for amastigotes, Figure 5, a). This finding suggests that the exclusion of 350 
compounds based on their lack of efficacy on cultured parasites could lead to the 351 
elimination of compounds very efficient on intracellular parasites, among which, 352 
inhibitors that kill indirectly parasites by targeting host cell proteins.  353 
 354 
Main library 355 
We selected seven out of twelve compounds from the main library including i) Rottlerin, 356 
NSC 146771, gefitinib and sunitinib, all potent against intracellular parasites at 10 μM, 357 
and ii) 5’ITu, PP2 (1-tert-butyl-3-(4-chlorophenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-358 
amine,(45)) and NSC 699479 that were efficient against intracellular parasites at 10 and 1 359 
μM as well as against cultured parasites (Table S1). 5’ITu, which is described as a 360 
general kinase inhibitor (46), is potent against promastigotes and axenic amastigotes, with 361 
an EC50 of 0.4 ± 0.1 and 5.4 ± 1.8 μM respectively (Table S1). It has also a strong effect 362 
at 10 and 1 μM on intracellular parasites with only 10 ± 1% and 13 ± 4.5% remaining PB, 363 
respectively, which is similar to 0.5 μM AMB. PP2 is potent against intracellular 364 
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amastigotes at 1 μM (54 ± 3% PB; Table S1). NSC 699479 (4-[(E)-[2-(4-chlorophenyl)-365 
1-methylpyrazolo[1,5-a]indol-1-ium-4-ylidene]methyl]-N,N-dimethylaniline;tri-fluorome 366 
thane-sulfonate) is known for anti-cancer activity and has been shown to target a wide 367 
range of proteins including the DNA polymerase iota (47). It is extremely potent against 368 
promastigotes and axenic amastigotes, with an EC50 below 1 μM as well as intracellular 369 
parasites at 10 μM (3.6 ± 1.9% PB), and 1 μM (11 ± 1.4% PB; Table S1), activity which 370 
is comparable to AMB.  371 
 372 
Purine library 373 
We selected 13 out of 21 purine compounds that were able to kill efficiently intracellular 374 
parasites at either 1 μM or 10 μM (compound 21 and 30, Table S1). Consistent with their 375 
high potency against recombinant LmCK1.2, most compounds were active against 376 
intracellular parasites. Surprisingly the purine derivatives were not very potent against 377 
promastigotes and axenic amastigotes. With the exception of compound 22 and 30, which 378 
present an EC50 of 0.72 ± 0.03 μM and 6.2 ± 0.8 μM against promastigotes respectively, 379 
most of the compounds were weakly active against promastigotes and inactive against 380 
axenic amastigotes at 50 μM (Table S1). This lack of potency against cultured parasites 381 
cannot be explained by cell permeability as these compounds efficiently decrease the 382 
parasite burden of infected macrophages.  383 
 384 
Indirubin library 385 
Fifty-five indirubins were tested against promastigotes and axenic amastigote. Twenty-386 
one compounds showed an EC50 below 10 μM against promastigotes (ranging from 0.4 to 387 
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2 μM) whereas only 6 showed an EC50 below 10 μM against amastigotes (ranging from 388 
3.5 to 8 μM). These compounds were all members of a subfamily of indirubins, 389 
containing a diethanolamine substitution in position-3’, suggesting that the presence of 390 
this substitution could be important for their anti-leishmanial activity against cultured 391 
parasites. It is remarkable that the EC50 against promastigotes was systematically lower 392 
than that against axenic amastigotes (21). We next tested all the indirubin derivatives 393 
against intracellular parasites. In contrast to purine derivatives, all indirubin compounds 394 
were efficient against intracellular parasites at 10 μM, with 9 also efficient at 1 μM 395 
(Table S1). The most efficient indirubin is compound 42 with a remaining 22 ± 5% PB, 396 
corresponding to a decrease of 78% compared to the DMSO-treated controls. Altogether, 397 
these data confirm what we observed with recombinant LmCK1.2 (Figure 4C and D) that 398 
the indirubin compound family, which has a stronger affinity for LmCK1.2 is also 399 
showing a higher anti-leishmanial activity. 400 
 401 
STEP 3: Evaluation of the toxicity of the compounds. 402 
Cytotoxicity against mouse Bone Marrow Derived Macrophages 403 
We first assessed the toxicity towards mouse bone marrow-derived macrophages of the 404 
75 compounds that displayed anti-leishmanial activity against intracellular parasites 405 
(Table S1, column VI%). We plotted the percentage of parasite burden versus the 406 
percentage of viable macrophages for each of the three libraries (Figure 6). As shown in 407 
Figure 6A, 3 compounds out of the 7 selected from the main library were toxic towards 408 
macrophages at 10 μM (Figure 6A, c, black dots) but none were toxic at 1 μM (Figure 409 
6A, b and d, grey dots). However, decreasing their concentration from 10 μM to 1 μM to 410 
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prevent cytotoxicity led, in some cases such as with sunitinib, to a decrease in potency 411 
against intracellular parasites. Nevertheless, we identified compounds that were not toxic 412 
and able to efficiently decrease PB (Figure 6A d). We obtained a similar result with the 413 
indirubin derivatives (Figure 6B, b and d) as we identified compounds with anti-414 
leishmanial activity and no toxicity against macrophages: 35 compounds at 10 μM and 9 415 
compounds at 1 μM (Figure 6B d). These results are in contrast to the results obtained for 416 
the purine library, as most of the 21 purine derivatives that we tested led to cell death, 417 
preventing proper analysis of their effect on intracellular parasites. Indeed, we did not 418 
identify any compound that decreased the percentage of parasite burden without 419 
cytotoxicity (Figure 6C, d). To investigate whether these derivatives could be efficient 420 
toward intracellular parasites at lower concentration, we tested compound 16, 22 and 30 421 
at 0.01 μM and 0.1 μM (data not shown). These compounds were no longer toxic to host 422 
cells at 0.1 μM, 0.1 μM and 0.01 μM respectively, and no longer active against 423 
intracellular parasites. It seems that the efficient concentration to kill intracellular 424 
parasites could be similar to the cytotoxic concentration. This finding could be explained 425 
by the higher affinity of this compound family for the mammalian CK1 compared to 426 
Leishmania CK1.2 (Figure 3B and C).  427 
Based on these results, we eliminated the sunitinib from the main library, all the 428 
remaining compounds from the purine library and 11 compounds from the indirubin 429 
library because of their toxicity against macrophages. We thus retained 6 compounds 430 
from the main library and 7 indirubins from those with anti-leishmanial activity at 1 μM 431 
and without cytotoxicity against BMDM.  432 
Cytotoxicity against human cell lines 433 
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To establish the selectivity index (SI, this unit corresponds to the ratio between the EC50 434 
against intracellular parasites and the EC50 against mammalian cells), we determined the 435 
EC50 against intracellular parasites, macrophages as well as human cell lines (RPE-1, 436 
SHSY-5Y, HFF-1 and U2OS, Table S1) for the remaining 13 compounds (Table S1). The 437 
SI ranged from 0.15 to 50, which is consistent with small molecules being able to 438 
discriminate between Leishmania CK1.2 and mammalian CK1, as we identified 439 
compounds that show leishmanicidal activity without cytotoxicity (Table S1). We 440 
eliminated all the compounds with a SI below 10, as they were likely to lead to side 441 
effects, retaining only five compounds: 5’ITu, PP2, NSC 699479 from the main library 442 
and compound 38 and 42 from the indirubin library. The EC50 of 5’ITu against 443 
intracellular parasites is in the nanomolar range (0.06 ± 0.01 μM) while that against 444 
mouse macrophages is in the micromolar range (3.5 μM ± 0), which represents a 60-fold 445 
difference between the cytotoxic and the anti-leishmanial concentrations (Table S1). The 446 
toxicity of this compound towards the human cell lines seems to be cell-dependent; 447 
indeed the EC50 against RPE-1 and U2OS is 1.2 μM, whereas it is above 25 μM against 448 
SHSY-5Y and HFF-1 (Table S1). Taking in account both cell lines and macrophages the 449 
minimum SI is thus 20, indicating that the leishmanicidal concentration is 20 fold lower 450 
than the toxic concentration. NSC699479 has also an EC50 against intracellular parasites 451 
in the nanomolar range (0.33 ± 0.05 μM) but a SI of only 10, due to the low EC50 towards 452 
macrophages and U2OS, respectively at 3.5 ± 0.24 μM and 3 ± 0.5 μM. Indirubin 38 has 453 
an EC50 of 0.6 ± 0.1 with a SI above 17, whereas compound 42, more potent, has an EC50 454 
of 0.06 ± 0.005 μM, with a high SI of 50 (Table S1). For PP2, it was impossible to 455 
determine the exact EC50, because the parasite burden at 10 μM of PP2 was 98 ± 8.5%, 456 
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whereas it was only 54 ± 3% at 1 μM. This result could be explained by the detachment 457 
of non-infected macrophages. Indeed, we showed that treatment of infected BMDM with 458 
10 μM of PP2 led to cell detachment as judged by the percentage of total remaining cells 459 
in the well (60 ± 1%, Table S1). We cannot completely exclude that cell detachment 460 
could be the consequence of cell mortality, but it seems unlikely, as the cells that 461 
remained attached were viable in the presence of the drug (VI of 83 ± 4%). This is 462 
consistent with what has been previously observed for other cell types, as PP2 is known 463 
to directly interfere with cell attachment (48). We estimated the EC50 of PP2 around 1 464 
μM as the PB is 54.3 ± 3.2 % at 1 μM (Table S1), with a SI above 10. For STEP4, we 465 
only selected 5’ITu, NSC699479, PP2 and compound 42 (Table 1).  466 
 467 
STEP 4: Target deconvolution. 468 
To confirm that 5’ITu, NSC699479, PP2 and compound 42 (Table 1) target Leishmania 469 
CK1.2 in the parasite and to estimate their affinity for this kinase, we investigated 470 
whether they could prevent the binding of CK1.2 to ATP-agarose (21). We treated 471 
amastigote lysates with PP2, 5’ITu, compound 42, NSC699479 or D4476 (positive 472 
control) before performing an affinity chromatography; we used an untreated sample as 473 
negative control. The proteins eluted from the ATP-agarose were separated by SDS-474 
PAGE and either stained with SYPRO-Ruby or analyzed by Western blotting using an 475 
anti-LmCK1.2 antibody (21). By comparing the protein elution profiles obtained with the 476 
untreated sample (Ama) to that obtained with the treated samples (D4476, PP2, Iodo, 73 477 
and 42) we were able to assess compound selectivity (Figure 7A). Most of the treated 478 
samples showed a profile similar to that of the untreated sample, except for the 5’ITu 479 
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(Figure 7A). As judged by the disappearance of several bands, 5’ITu could be targeting 480 
many ATP-binding proteins aside CK1.2. Because this absence of selectivity prevents 481 
any possibility for compound optimization, which could in turn lead to side effects, we 482 
eliminated 5’ITu. Based on the Western blot analysis, we also discarded NSC699479, as 483 
LmCK1.2 could still bind to the ATP beads in presence of this compound, suggesting that 484 
this kinase is not the primary target of NSC699479 (Figure 7B). This is consistent with 485 
the fact that the IC50 of NSC699479 against LmCK1.2 is 8 μM, which is higher than that 486 
of the other compounds (Table S1). However because of its strong anti-leishmanial 487 
activity, it would be interesting to identify the primary target of NSC699479. As shown 488 
in Figure 7B, similarly to D4476, only PP2 and compound 42 prevent the binding of 489 
LmCK1.2 to the ATP beads without affecting the elution profile. This result suggests that 490 
LmCK1.2 could be one of the primary targets of these two compounds.  491 
 492 
DISCUSSION 493 
The anti-leishmanial drugs currently available are compromised mostly because they lead 494 
to parasite resistance and have important side effects. Considering these parameters early 495 
in the process of drug development is therefore crucial to discover more efficient drugs. 496 
We established a pipeline consisting of 4 steps from target-based screening to target 497 
deconvolution. In order to integrate these parameters, we used LmCK1.2 (a Leishmania 498 
exo-kinase) as a target to address parasite resistance, and excluded compounds based on 499 
their absence of anti-leishmanial activity, on their lack of specificity or on their poor 500 
affinity for LmCK1.2 to address side effects. Our pipeline introduces two improvements 501 
compared to previous screening campaigns. First, as Leishmania and mammalian CK1s 502 
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are closely related and to limit the possibility of cell toxicity, which leads to side effects, 503 
we screened, in parallel, the leishmanial and mammalian CK1 to assess specificity. Using 504 
this approach we could discriminate between compounds with low and high specificity. 505 
For instance, we showed that the purine derivatives displayed a better potency against 506 
mammalian CK1 than against LmCK1.2, which led to toxicity against mammalian host 507 
cells. Reversely, compounds of the indirubin family displayed a better potency against 508 
LmCK1.2 than mammalian CK1, which was subsequently confirmed by their absence of 509 
toxicity toward the mammalian host cell at 1 μM. This finding suggests that a strong 510 
correlation between the specificity toward the target and the subsequent effect on 511 
intracellular parasite survival. Moreover, our results also confirm that LmCK1.2 has an 512 
ATP binding pocket sufficiently divergent from that of mammalian CK1 to identify 513 
discriminating compounds (21). Indeed, more than 70% of the small molecules that we 514 
tested showed a differential potency against both kinases. We modelled the structure of 515 
Leishmania CK1.2 based on existing crystal structures of CK1s found in Protein Data 516 
Bank and noticed a few differences between the LmCK1.2 model (green, Figure S2) and 517 
the crystal structure of human CK1δ or of Schizosaccharomyces pombe CK1 (magenta or 518 
cyan (SpCK1) respectively, Figure S2) that could account for the specificity of LmCK1.2 519 
towards certain compounds. Indeed, residues in the active site of LmCK1.2 such as F22 520 
and K40 could be positioned differently, which could overall change the shape of the 521 
active site. Moreover, the structural alignment of LmCK1.2, human CK1δ and SpCK1 522 
(49), which is in complex with IC261 (specific CK1 inhibitor) shows that the position of 523 
K40 in the active site of LmCK1.2 compared to that of K41 or K38 in the active site of 524 
CK1δ and SpCK1 respectively, may account for the differential response to compound 525 
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inhibition. Indeed, contrary to K38 and K41, K40 could lead to conformational clash with 526 
IC261. This finding supports our previous results showing that the IC50 of IC261 towards 527 
LmCK1.2 is above 10 μM whereas it is 0.47 μM towards mammalian CK1 (21). Our 528 
results demonstrate that Leishmania CK1.2, which would have been rejected based on the 529 
strong identity to its mammalian orthologs, is a good drug target.  530 
A second improvement was to assess whether compounds have multiple targets or low 531 
affinity for LmCK1.2. To address this issue, we performed target deconvolution. This 532 
strategy, which depends on affinity purification and competition, allowed the elimination 533 
of compounds based on their lack of specificity or their lack of affinity towards 534 
LmCK1.2. Indeed, we excluded 5’ITu that could be targeting many proteins as revealed 535 
by their depletion following competition assay and ATP-affinity chromatography. This 536 
finding is consistent with recent publications showing that 5’ITu is a general kinase 537 
inhibitor due to its broad inhibitory activity (46). Although this compound could be a 538 
good lead compound purely based on its SI, its optimisation could be difficult as the 539 
target responsible for the leishmanicidal activity is unknown. We also excluded 540 
NSC699479 because of its weak affinity towards LmCK1.2, suggesting that this kinase 541 
might not be its primary target. Based on previous results in mammalian cells, the 542 
primary target of NSC699479 could be topoisomerases in Leishmania, enzymes already 543 
known as good drug targets (50) (51) (52). 544 
 545 
Using this pipeline, we screened 5018 compounds in total and identified two lead 546 
compounds, PP2 and compound 42. PP2 is an inhibitor for which no anti-leishmanial 547 
activity against intracellular parasites in THP-1 cells in vitro has been previously 548 
 25
described but appears to be efficient in animal model (53). It has an EC50 on intracellular 549 
parasites around 1 μM, but a selectivity index above 10 for murine macrophages and 550 
above 25 for human cell lines. The known targets of PP2 are tyrosine kinases, Src, Lck, 551 
Csk, Rip2 and Gak, for which there are no orthologs identified in Leishmania (54, 55). 552 
The two other kinases that are targeted by PP2 are p38 (52% of inhibition at 1 μM (54)) 553 
and CK1δ (93% of inhibition at 1 μM (54)), suggesting that the anti-leishmanial activity 554 
of PP2 is more likely mediated by the inhibition of CK1.2 in Leishmania. This finding is 555 
consistent with our experimental data showing that Leishmania CK1.2 is one of the 556 
primary targets of PP2. However, treatment with high concentrations of PP2 leads to 557 
macrophage detachment (40% at 10 μM) similarly to what has been shown previously for 558 
other cell types (48). Our results seem to indicate that most of the macrophages that 559 
detach from the slides are those non-infected by Leishmania. This hypothesis is supported 560 
by Tejle et al, which showed that the presence of L. donovani affect the detachment of 561 
monocyte-derived dendritic cells, suggesting that the presence of the parasite could 562 
promote cell adhesion (56).  563 
Indirubins are particularly potent against cultured as well as intracellular parasites and 564 
among the 55 indirubin derivatives showing leishmanicidal activity at 10 μM, only 37% 565 
were cytotoxic against macrophages. Compound 42 is our best lead compound, with an 566 
EC50 on intracellular parasites of 60 ± 5 nM and a SI of 50. Although several authors 567 
have already described the anti-leishmanial effect of indirubins (57-59), this particular 568 
derivative has not been previously tested on intracellular parasites. From previous 569 
published work, we already know some of the targets of the indirubins, such as 570 
Leishmania CRK3 or GSK3 (57, 58). In our study, we reveal for the first time CK1.2 as a 571 
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novel target for this family of compounds. This is particularly striking as in higher 572 
eukaryotes GSK3 and CK1 are often involved in similar signalling pathways such as the 573 
Wnt/β-catenin or the Hedgehog pathways, where they act as priming kinases for one 574 
another (60, 61) (62) (63). Using affinity purification, we found that GSK-3 is also a 575 
target of compound 42 (data not shown). We will determine precisely, using biochemical 576 
approaches, whether this compound targets other kinases and which one causes the anti-577 
leishmanial effect. 578 
 579 
In conclusion, we have established a comprehensive pipeline that identify and select 580 
LmCK1.2 inhibitors based on their specificity, anti-leishmanial activity, absence of 581 
cytotoxicity and selectivity. As a proof of principle, we identified two lead compounds, 582 
PP2 and compound 42 that will be studied further to understand their mode of action and 583 
could also be used as pharmacological tools to study parasite-specific signal transduction. 584 
We will use this pipeline to screen diversified libraries that have not yet been screened 585 
against Leishmania kinases, in order to identify lead compounds. 586 
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 796 
FIGURE LEGENDS 797 
FIGURE 1. Differential target-based screen of 4030 compounds from various 798 
libraries. A. Representation of the percentage of inhibition towards LmCK1.2 activity 799 
versus the percentage of inhibition toward SsCK1 activity. Compounds in a and b are 800 
potent toward LmCK1.2 as they show more than 40% inhibition, whereas compounds in 801 
b and d are potent toward SsCK1. B. 336 hit compounds were identified in the screen 802 
from which 245 inhibit SsCK1 (6.1 % hit rate) and 128 inhibit LmCK1.2 (3.2% hit rate). 803 
Only 37 compounds showed equal potency against both CK1s. C. Compounds were 804 
classified according to their specificity: compounds only potent against SsCK1 (only 805 
SsCK1), more potent against SsCK1 than LmCK1.2 (SsCK1 > LmaCK1.2), equally 806 
potent on both kinases (SsCK1 = LmCK1.2), more potent against LmCK1.2 than SsCK1 807 
(SsCK1 < LmaCK1.2) and only potent on LmCK1.2 (only LmCK1.2). Compounds were 808 
also classified according to their % of inhibition: Class 1 corresponds to compounds that 809 
inhibit the kinases activity between 80-100%, Class 2 between 60-80% and class 3 810 
between 40-60%. Twenty-three compounds are more potent toward LmCK1.2 than 811 
SsCK1 and 68 compounds are specific to LmCK1.2 (the numbers in the histograms 812 
indicate the percentage of compounds in each category). 813 
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 814 
FIGURE 2. Determination of the IC50 of the 45 compounds belonging to Class 1 that 815 
have a percentage of inhibition above 90%. Each point represents the IC50 of a 816 
particular compound towards LmCK1.2. Non-specific compounds have a potency below 817 
10 μM towards both kinases, whereas specific compounds have a potency below 10 μM 818 
only towards LmCK1.2.  819 
 820 
FIGURE 3. Screening of the purine derivative library. A. Structure of the purine 821 
backbone. R1, R2 and R3 represent different substitutions of the purines. B. We 822 
performed a target-based screening of 588 derivatives. Each point represents the 823 
percentage of inhibition towards LmCK1.2 activity versus the percentage of inhibition 824 
towards SsCK1 activity of each compound. The compounds in the top left are more 825 
potent toward LmCK1.2 whereas the compounds in the bottom right are more potent 826 
towards SsCK1. C. Compounds were classified according to their specificity: only potent 827 
on SsCK1, more potent on SsCK1 than LmCK1.2 (SsCK1 > LmCK1.2), equally on both 828 
kinases (SsCK1 = LmCK1.2), more potent on LmCK1.2 than SsCK1 (SsCK1 < 829 
LmCK1.2) and only potent on LmCK1.2. Compounds were also classified according to 830 
their % of inhibition: Class 1 corresponds to compounds that inhibit the kinases between 831 
80-100%, Class 2 between 60-80% and class 3 between 40-60%. Only 4 percent of the 832 
compounds are more potent toward LmCK1.2 than SsCK1 or specific to LmCK1.2. D. 833 
We determined the IC50 of the 21 compounds belonging to class 1 that have a percentage 834 
of inhibition above 90%. Each point represents the IC50 of a particular compound towards 835 
LmCK1.2 versus SsCK1. The IC50 are lower towards SsCK1 than LmCK1.2. 836 
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 837 
FIGURE 4. Screening of the indirubin derivative library. A. Structure of the indirubin 838 
backbone. B. Target-based screening of 400 derivatives. Each point represents the 839 
percentage of inhibition towards LmCK1.2 activity versus the percentage of inhibition 840 
toward SsCK1 activity for each compound. The compounds in the top left are more 841 
potent towards LmCK1.2 whereas the compounds in the bottom right are more potent 842 
towards SsCK1. C. Compounds were classified according to their specificity: only potent 843 
on SsCK1, more potent on SsCK1 than LmCK1.2 (SsCK1 > LmaCK1.2), equally on both 844 
kinases (SsCK1 = LmCK1.2), more potent on LmCK1.2 than SsCK1 (SsCK1 < 845 
LmaCK1.2) and only potent on LmCK1.2. Compounds were also classified according to 846 
their % of inhibition: Class 1 corresponds to compounds that inhibit the kinases between 847 
80-100%, Class 2 between 60-80% and class 3 between 40-60%. Fifty-seven percent of 848 
the compounds are more potent towards LmCK1.2 than SsCK1 and 46% are specific to 849 
LmCK1.2. D. IC50 of the 55 compounds that are specific to LmCK1.2 or that belong to 850 
class 1 with a percentage of inhibition above 90%. Each point represents the IC50 of a 851 
particular compound towards LmCK1.2 versus SsCK1. The IC50 are lower against 852 
LmCK1.2 than SsCK1. 853 
 854 
FIGURE 5. Comparaison of the anti-leishmanial activity of compounds on cultured 855 
and intracelular parasites. We performed a screening of 88 compounds from the main, 856 
the purine and the indirubine libraries on cultures promastigotes, axenic amastigotes and 857 
intracellular parasites. Each point represents the percentage of metabolically active 858 
promastigotes or amastigotes at 10 μM versus the percentage of parasite burden at 10 μM 859 
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for each compound. Black squares correspond to the percentage of metabolically active 860 
promastigotes at 10 μM versus the percentage of parasite burden at 10 μM and grey dots 861 
correspond to the percentage of metabolically active amastigotes at 10 μM versus the 862 
percentage of parasite burden at 10 μM. a: compounds that are potent against intracellular 863 
parasites but not against cultured parasites, b: compounds that are not potent against 864 
intracellular and cultured parasites, c: compounds that are potent against intracellular and 865 
cultured parasites and d: compounds that are not potent against intracellular but potent 866 
against cultured parasites.  867 
 868 
FIGURE 6. Parasite burden versus macrophage viability. Using a visual high content 869 
phenotypic assay, we calculated the percentage of viable macrophages and the percentage 870 
of infected cells. We analysed the anti-leishmanial effect of the selected compounds from 871 
the main library (A), the indirubin library (B) and the purine library (C) versus their 872 
toxicity against macrophages. a: compounds that are not potent against intracellular 873 
parasites but cytotoxic, b: compounds that are not potent against intracellular parasites 874 
and not cytotoxic, c: compounds that are potent against intracellular but cytotoxic and d: 875 
compounds that are potent against intracellular and not cytotoxic.  876 
 877 
FIGURE 7. PP2 and compound 42 are the most specific compounds towards CK1.2. 878 
Competitive ATP affinity chromatography assays were performed on amastigote cell 879 
lysates in presence or not of D4476, PP2, 5’ITu (Iodo), NSC699479 (73) and 42. ATP-880 
binding proteins (Elution) were eluted with an excess of ATP, resolved by SDS-PAGE 881 
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electrophoresis and stained by SYPRO Ruby (A). CK1.2 was revealed by Western blot 882 
using an anti-LmCK1.2 antibody (SY3535, B). 883 
 884 
FIGURE S1. Controls for the phenotypic screen. We analysed the effect of DMSO, 885 
AMB and CHX on intracellular parasites using a visual high content phenotypic assay. 886 
We assessed several parameters including the percentage of total cells compared to 887 
control cells with DMSO (TM%), the percentage of viable cells (VI%) and the 888 
percentage of viable cells with parasitophorous vacuoles that is considered as an 889 
indication of parasite burden (PB%).  890 
 891 
FIGURE S2. Model of the ATP binding pocket of LmCK1.2 compared to that of 892 
human and yeast CK1s. Comparison of yeast (cyan) and human (magenta) CK1 crystal 893 
structures with a structural model of LmCK1.2 (green). IC261 is represented in the ATP-894 
binding pocket. 895 
 896 
 897 
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 898 
  899 
 900 
 901 
Table 1: Selected compounds against intracellular parasites tested for target deconvolution. 
*: Estimation of the EC50. 







FIGURE S1. Controls for the phenotypic screen. We analysed the effect of DMSO, AMB and CHX on 
intracellular parasites using a visual high content phenotypic assay. We assessed several parameters 
including the percentage of total cells compared to control cells with DMSO (TM%), the percentage of 
viable cells (VI%) and the percentage of viable cells with parasitophorous vacuoles that is considered as an 
indication of parasite burden (PB%).  
 
FIGURE S2. Model of the ATP binding pocket of LmCK1.2 compared to that of human and yeast 
CK1s. Comparison of yeast (cyan) and human (magenta) CK1 crystal structures with a structural model of 
LmCK1.2 (green). IC261 is represented in the ATP-binding pocket. 
 Number Name SsCK1 LmCK1.2 50 µM 10 µM 50 µM 10 µM proma-stigote
ama-
stigote TM % PB % VI % TM % PB % VI % RPE-1 SHSY-5Y HFF-1 U2OS
1 PKC-412 >10 ≥10 63.8 85.0 102.2 93.0 > 50 > 50 n.d. n.d. n.d. n.d. n.d. n.d.
2 Hypericin >10 6.2 76.5 127.4 92.9 106.0 > 50 > 50 n.d. n.d. n.d. n.d. n.d. n.d.
3 5-Iodotubercidin 0.1 0.2 14.5 22.7 25.2 39.0 0.4 5.0 77.0 10.2 9.3 68.0 13.0 90.0 0.1 3.5 1.2 > 25 > 25 1.2 20
4 SB-202190 0.4 0.1 69.0 129.4 112.3 111.0 > 50 > 50 87.7 72.8 89.4 94.9 83.6 93.5
5 PP2 0.5 1.4 41.2 114.0 99.1 101.0 > 10 > 50 59.9 97.6 82.9 83.7 54.3 97.8 1* > 10 > 25 > 25 > 25 > 25 > 10
6 GW 5074 4.3 4.9 27.5 112.8 20.3 72.0 > 10 > 10 102.9 82.5 97.6 101.7 79.1 94.1 3* > 10 > 50 > 50 > 50 39.0 > 3.3
7 Rottlerin ≥10 4.9 15.7 90.2 32.2 104.0 > 10 > 10 58.5 12.1 93.4 101.8 82.0 79.1
8 Indirubin-3'-
monoxime 0.4 0.1 70.1 125.0 85.2 110.0 > 50 > 50 99.6 75.2 96.5 104.9 80.5 95.9
9 BML-265 2.2 0.9 36.9 124.0 87.2 126.0 > 10 > 50 96.1 66.8 95.6 104.0 80.9 96.4
10 0.1 0.4 13.8 51.8 49.8 99.0 > 10 > 10 54.5 64.9 65.8 105.1 80.4 87.4
11 1.6 1.8 27.9 68.4 83.2 101.0 > 10 > 50 67.5 79.1 90.0 98.9 83.1 95.3
12 0.2 1.3 18.1 83.3 56.4 97.0 > 10 > 50 90.9 65.8 89.7 108.2 79.7 88.7
13 0.8 0.9 61.9 102.6 104.3 100.0 > 50 > 50 100.5 88.4 96.4 104.3 83.8 94.3
14 0.4 0.5 90.7 104.3 109.1 104.0 > 50 > 50 88.1 74.8 94.6 94.6 81.8 95.7
15 0.8 0.8 26.1 64.8 77.9 95.0 > 10 > 50 84.8 81.4 95.8 103.6 87.9 95.6
16 0.1 0.7 54.3 114.6 100.3 101.0 > 10 > 50 64.3 77.0 27.6 52.1 74.0 48.5
17 0.3 1.0 35.0 116.5 78.5 96.0 > 10 > 50 61.7 51.5 15.2 61.2 58.6 18.6
18 0.1 0.9 43.1 95.8 81.0 103.0 > 10 > 50 62.7 57.8 17.3 67.8 50.5 13.6
19 0.1 0.7 31.2 110.1 86.3 94.0 > 10 > 50 64.8 66.2 19.3 65.0 55.2 15.6
20 0.6 1.1 44.2 105.0 92.9 94.0 > 10 > 50 55.6 67.4 26.6 57.1 54.6 19.6
21 1.1 2.4 10.6 104.0 99.8 104.0 > 10 > 50 85.1 18.1 8.5 79.5 87.0 82.2
22 0.7 1.2 9.9 12.1 19.6 75.0 0.8 > 10 106.9 0.0 37.1 115.2 17.6 23.9
23 0.2 1.3 18.3 83.7 70.5 89.0 > 10 > 50 70.5 32.5 12.0 69.0 51.5 7.8
24 0.1 1.5 19.7 92.5 61.1 98.0 > 10 > 10 71.5 23.4 11.5 69.2 59.9 10.3
25 0.2 1.7 15.3 119.3 58.2 104.0 > 10 > 50 71.0 18.8 12.1 72.7 51.7 10.1
26 3.7 1.0 89.9 135.9 78.2 98.0 > 50 > 50 95.0 80.0 90.4 102.1 84.5 92.8
27 1.2 1.4 16.9 100.5 74.5 94.0 > 10 > 50 78.6 33.1 11.0 79.0 57.5 9.3
28 0.4 1.2 27.6 103.4 84.1 94.0 > 10 > 50 59.3 58.2 23.7 68.9 49.6 14.7
29 0.1 0.7 84.8 121.8 101.4 99.0 > 50 > 50 49.0 66.2 48.5 56.8 57.0 22.6
30 1.3 1.5 15.0 31.7 27.5 64.2 6.5 > 10 58.9 45.8 46.2 77.8 65.5 9.8
31 2.2 1.0 39.3 75.9 57.0 93.0 > 10 > 50 95.6 51.5 94.5 103.9 81.1 93.3
32 0.7 0.6 71.8 73.6 63.2 94.3 > 50 > 50 92.7 48.7 96.2 104.2 84.8 92.0
33 3.5 2.1 69.2 113.7 59.7 103.7 > 50 > 50 80.1 50.7 96.8 104.2 81.5 93.7
34 0.3 0.2 69.9 92.0 58.3 96.8 > 50 > 50 87.8 32.6 98.6 104.9 78.7 92.6
35 1.0 0.2 81.7 105.7 86.9 105.6 > 50 > 50 79.3 45.2 93.6 103.6 78.2 90.2
36 0.6 0.2 79.8 101.3 92.8 106.8 > 50 > 50 83.9 42.0 97.3 101.4 85.4 92.2
37 0.7 0.7 122.5 121.3 101.2 103.7 > 50 > 50 107.9 53.3 96.5 105.3 77.0 93.0
38 0.7 1.2 56.5 122.0 72.8 115.1 > 10 > 50 106.6 25.9 98.8 110.5 68.1 95.5 0.6 > 10 > 25 > 25 > 25 > 25 > 17
39 1.1 0.5 32.0 121.8 32.9 100.9 > 10 > 10 97.7 39.2 98.6 106.7 82.3 93.4
40 0.3 0.1 38.4 93.2 48.8 82.2 > 10 > 10 96.9 44.1 98.2 103.8 79.1 93.0
41 1.3 0.7 131.9 146.7 118.9 97.4 > 50 > 50 101.3 5.5 2.3 98.6 81.0 93.9
42 2.1 0.9 9.3 11.6 19.3 59.6 2.0 > 10 106.0 0.0 0.5 107.1 46.7 95.4 0.1 3.0 7.0 18.0 7.7 7.3 50
43 0.7 0.7 10.9 48.7 26.6 29.6 1.0 8.0 83.9 22.8 15.3 102.6 72.0 92.3
44 1.2 0.5 8.8 10.5 19.9 22.8 0.9 4.5 106.9 0.0 0.7 96.0 71.4 93.1
45 1.2 0.4 9.4 10.7 20.5 22.1 0.7 4.5 106.6 0.0 1.2 103.0 74.4 90.8
46 >10 4.2 10.1 106.7 25.3 73.6 > 10 > 10 103.2 44.1 99.0 105.1 81.6 93.4
47 >10 5.2 9.7 13.0 23.0 95.2 2.0 > 10 75.6 23.4 13.5 107.5 79.2 97.2
48 10.0 5.1 9.5 10.5 19.6 27.5 0.4 7.0 74.1 0.0 0.3 112.6 53.9 99.0
49 1.2 0.7 9.7 12.7 23.5 80.8 2.0 >10 83.5 24.6 46.1 106.0 66.2 96.5
50 1.1 0.7 7.9 10.4 19.7 21.0 0.7 3.5 107.4 0.0 0.2 108.7 68.6 96.9
51 >10 8.5 98.0 106.3 96.0 97.1 > 50 > 50 111.7 51.0 98.0 104.1 74.8 91.2
52 0.2 0.1 106.9 118.6 90.0 86.9 > 50 > 50 103.6 61.6 95.9 102.4 85.1 89.9
53 >10 10.0 67.3 103.5 64.3 94.7 > 50 > 10 81.8 45.8 95.7 105.0 84.8 91.4
54 1.3 0.8 68.0 95.2 84.2 93.3 > 50 > 50 114.7 50.4 98.8 111.6 81.9 92.6
55 >10 5.3 99.0 107.7 88.2 96.3 > 50 > 50 118.1 60.9 96.8 111.2 83.2 93.0
56 >10 8.0 96.0 101.8 98.7 100.4 > 50 > 50 106.2 54.6 95.8 111.8 80.1 93.3
57 >10 10.0 9.4 90.3 19.2 72.2 > 10 > 10 97.0 0.1 6.8 114.4 81.9 90.7
58 9.2 7.3 79.3 94.2 26.9 83.0 > 50 > 10 106.8 63.7 95.8 109.8 81.2 92.2
59 0.2 0.1 85.7 94.6 57.7 82.5 > 50 > 10 86.5 34.3 98.0 106.8 77.8 92.7
60 >10 3.2 10.2 15.0 27.6 64.4 2.0 >10 70.7 26.5 70.1 105.9 69.5 95.0
61 >10 7.3 20.2 81.5 14.8 21.9 n.d. 5.0 43.8 1.0 11.3 110.1 81.4 91.6 2.0 2.0 n.d. n.d. n.d. n.d. 1
71 NSC 146771 >10 1.5 59.2 116.3 108.9 119.4 > 10 > 50 104.3 55.2 98.2 102.6 73.3 93.0
72 NSC 610744 >10 7.0 104.2 112.6 99.7 109.1 > 50 > 50 104.0 78.1 88.0 105.1 84.3 93.1
73 NSC 699479 >10 8.0 n.d n.d n.d n.d < 1 < 1 107.9 3.6 4.7 105.4 10.9 97.5 0.3 3.5 10.5 36.5 12.0 3.0 12
74   NSC 715055 
(gefitinib) >10 2.0 19.7 97.9 111.3 102.7 > 10 > 50 93.0 42.7 98.4 102.5 79.2 93.4 8.0 > 10 n.d. n.d. n.d. n.d. > 1.3
75 NSC 750690 
(sunitinib) 0.8 0.6 8.5 13.1 96.3 111.5 4.0 > 50 88.3 0.0 0.1 79.1 86.6 91.1 2.5 3.0 n.d. n.d. n.d. n.d. 1.2
77 purvalanol B 2.9 2.0 n.d. n.d. n.d. n.d. n.d. n.d. 91.76 88.27 82.84 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
80 4.6 1.7 7.6 8.0 21.1 112.6 1.8 > 10 66.7 39.7 92.2 105.7 67.5 97.0
81 8.0 2.0 5.9 8.0 18.7 108.3 2.3 > 10 80.8 15.8 20.9 109.8 57.1 98.0
82 >10 4.2 7.9 9.3 39.7 122.1 2.5 > 10 103.3 0.7 0.8 109.2 65.2 96.6
84 ≥10 9.2 7.0 8.1 17.9 49.8 0.7 > 10 86.3 0.0 0.3 113.3 56.1 97.8 1.5 2.5 2.3 6.0 2.2 2.0 1.5
85 -(10) >10 36.7 104.0 19.3 111.2 > 10 > 10 110.7 21.5 52.0 107.4 79.5 90.9
86 2.2 1.1 5.7 7.2 16.4 100.3 2.0 > 10 87.0 29.7 23.7 106.3 56.1 97.4 2.0 4.5 n.d. n.d. n.d. n.d. 2.3
87 2.8 1.4 7.2 7.4 20.3 116.9 1.7 > 10 64.6 35.9 81.4 99.8 65.1 95.0
88 >10 >10 92.6 107.7 104.1 105.9 > 50 > 50 115.6 52.6 98.4 108.4 79.2 93.6
89 1.4 0.6 8.0 12.1 39.8 114.0 2.0 > 10 113.2 0.0 0.7 110.2 81.6 91.7
90 >10 >10 18.3 94.8 104.8 112.9 > 10 > 50 108.5 45.7 97.3 111.1 84.2 90.8
91 1.0 0.9 8.6 79.5 81.6 110.5 > 10 > 50 117.3 0.0 0.5 112.5 55.7 97.2 1.5 3.0 2.2 4.5 2.3 0.8 0.5
92 >10 >10 30.6 101.7 94.5 109.6 > 10 > 50 98.0 38.3 99.1 113.2 85.2 91.5
93 ≥10 >10 7.6 8.5 22.3 107.2 1.6 > 10 91.3 44.9 94.4 109.8 83.6 93.4
94 0.2 0.3 7.6 11.8 75.6 103.5 1.8 > 50 98.8 23.4 1.0 103.0 47.9 97.8 0.7 3.0 2.0 14.0 10.0 0.7 1
95 2.2 2.4 64.8 98.5 63.3 100.4 > 50 > 50 85.3 54.9 97.2 101.7 83.1 90.5
96 0.8 2.2 6.4 74.7 18.3 85.4 > 10 > 10 96.7 55.9 96.1 105.4 81.1 90.1
97 >10 >10 8.4 15.1 19.7 48.0 8.0 > 10 102.8 43.4 98.8 111.5 84.4 88.5 4.0 > 10 > 25 > 25 15.0 > 25 > 2.5
98 >10 >10 35.7 107.3 21.4 94.7 > 10 > 10 108.4 39.9 93.7 106.3 79.3 92.1
99 0.7 0.8 8.0 82.6 59.6 69.5 > 10 > 10 114.6 32.0 97.1 110.5 71.1 95.3
100 >10 >10 18.2 108.6 101.9 88.7 > 10 > 50 120.3 57.1 97.7 113.5 80.9 90.0
101 1.1 0.6 7.2 15.7 33.0 94.3 6.5 > 10 123.9 33.2 98.9 114.4 74.1 93.6
102 0.2 0.2 39.7 62.6 66.2 76.0 > 10 > 10 65.5 41.6 91.0 93.3 52.7 92.9 2.0 > 10 0.8 > 25 9.0 0.3 0.15
103 0.4 0.2 7.8 102.5 76.8 96.3 > 10 > 50 99.1 0.0 0.5 100.3 75.3 92.5
104 1.5 0.9 6.1 8.3 18.7 101.4 5.0 > 10 66.0 34.2 93.6 103.4 79.4 89.3
 Metabolically active cells (%) intracellular parasites Macrophage 
viability EC50 
(µM)
EC50 against human cells (µM) Selectivity 
Index (SI)
Compound IC50 (µM) Promastigote (%) amastigote (%) EC50 (µM) 10 µM 1 µM
EC50 (µM)
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